Scholarlink

<p>Dexrazoxane prevents anthracycline-induced cardiotoxicity and treats anthracycline extravasation. Although thrombosis is not a commonly observed adverse effect of dexrazoxane, a potential association has been suggested. We present three patients (four episodes) who experienced decreased antithrombin activity after dexrazoxane administration. All patients were prescribed dexrazoxane to protect soft tissues from anthracycline extravasation during chemotherapy for hematological malignancies. This led to a reduction in antithrombin activity after a median of 4 days from the first dexrazoxane injection. The activity levels recovered several days later, and one patient developed deep-vein thrombosis. There was no apparent explanation other than dexrazoxane use, raising the possibility that dexrazoxane may be associated with decreased antithrombin activity. We hypothesize that this decrease in antithrombin activity may contribute to thrombosis after dexrazoxane injection. Based on these cases and a review of previous reports on dexrazoxane and thrombosis, it is recommended that clinicians monitor antithrombin decline and thrombosis development in patients undergoing dexrazoxane treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Dexrazoxane reduces antithrombin activity: a case series

  • 期刊论文

  • 发表日期：

    2026年2月13日

查看全文
  • Tomohiro Nagano,
  • Kaho Makiuchi,
  • Akifumi Matsumura,
  • Daigo Niiya,
  • Soichiro Fujii,
  • Makoto Takeuchi

摘要

Dexrazoxane prevents anthracycline-induced cardiotoxicity and treats anthracycline extravasation. Although thrombosis is not a commonly observed adverse effect of dexrazoxane, a potential association has been suggested. We present three patients (four episodes) who experienced decreased antithrombin activity after dexrazoxane administration. All patients were prescribed dexrazoxane to protect soft tissues from anthracycline extravasation during chemotherapy for hematological malignancies. This led to a reduction in antithrombin activity after a median of 4 days from the first dexrazoxane injection. The activity levels recovered several days later, and one patient developed deep-vein thrombosis. There was no apparent explanation other than dexrazoxane use, raising the possibility that dexrazoxane may be associated with decreased antithrombin activity. We hypothesize that this decrease in antithrombin activity may contribute to thrombosis after dexrazoxane injection. Based on these cases and a review of previous reports on dexrazoxane and thrombosis, it is recommended that clinicians monitor antithrombin decline and thrombosis development in patients undergoing dexrazoxane treatment.